TCRT Alaunos Therapeutics, Inc. - 8-K

Item 8.01 - Other Events.

On May 26, 2026, Alaunos Therapeutics, Inc. (the “Company”) issued a press release announcing an integrated preclinical readout for ALN1003, the Company’s investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders. The release summarizes findings from two non-Good Laboratory Practice (“non-GLP”) diet-induced obesity mouse studies, including results previously reported on March 2, 2026 and May 18, 2026, together with additional cross-study analyses included in an accompanying non-confidential investor presentation. The reported findings are based on non-GLP preclinical studies and should be interpreted with appropriate caution, as ALN1003 has not been evaluated in human clinical trials and its safety and efficacy in humans have not been established.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 8.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release, dated May 26, 2026

99.2

Investor Presentation, dated May 26, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)